semaglutide new zealand Pharmac (Te Pātaka Whaioranga) in is currently seeking #clinical #advice on whether to fund weight loss #medications like (marketed as Wegovy for weight loss or Ozempic for type 2diabetes) Find out more about the

It's an obvious risk, of course, but it's also what sets apart disruptors from the rest

The share of covered workers in a plan with a general annual deductible of $2,000 or more for single coverage has increased 32% over the last five years and 77% over the last ten years [Figure F]

GLP-1RAs vs second- or third-line glucose-lowering medications (sensitivity analysis) We conducted the first sensitivity analysis to compare GLP-1RAs with second- or third-line glucose-lowering medications

Oral GLP-1s are probably the most anticipated innovation within this category, given their convenient, non-invasive nature relative to current injectable formulations